India is the second worse hit country in the world by the Coronavirus, although the government is expecting to control and slow down the Covid-19 outbreak.
The Indian government has a target to vaccinate around 25 crore Indians by the mid of next year. However, the authorities are looking for multiple vaccines option to immunize the large population.
Let’s have a look at some of the vaccine which is likely to get approval and on the various stage of trails.
AZD1222 of Oxford University and AstraZeneca
This vaccine is getting developed by AstraZeneca pharmaceutical company and Oxford University, and currently its in the clinical trial phase-3 in India.
Serum Institute of India, the Pune based pharmaceutical company is partnered with AstraZeneca to develop the Covid-19 vaccine and it will be sold as Covishield.
Scientists are expecting that this can be the first Coronavirus vaccine which will be available in the market, they are expecting to get the regulatory approvals by end of this year.
Based on the current reports Covishield’s recent trials have not developed any negative effects on the participants. In a report, a scientist has mentioned that very few people have got fevers after getting the doses, and these are just mild reactions and to be worried about on a high level.
COVAXIN by Bharat Biotech
Indian company Bharat Biotech is developing a vaccine called, COVAXIN and currently, it’s in the Phase-2 trial. The vaccine is developed with a collaboration with ICMR and NIV. The company has also requested the drug regulator for the third phase of the trial of the vaccine.
ZyCoV-D of Zydus Cadila
Zydus Cadila, the Hyderabad based company is also developing the vaccine called ZyCoV-D, the vaccine is in trials of phase-2. The Chairman of Zydus Cadila Pankaj R Patel informed the media last month and said the trials are on the right track and they are expecting the result by the November end and they are hoping to roll out the vaccine by next year March.
There are few other companies trying to develop the coronavirus vaccine and in different phases of trials.